Javier Sabater
Jazz Pharmaceuticals (United States)(US)Vertex Pharmaceuticals (United Kingdom)(GB)Jazz Pharmaceuticals (Italy)(IT)Health Economics and Outcomes Research (United Kingdom)(GB)Jazz Pharmaceuticals (Ireland)(IE)Jazz Pharmaceuticals (France)(FR)
Publications by Year
Research Areas
Health Systems, Economic Evaluations, Quality of Life, CAR-T cell therapy research, Cancer Immunotherapy and Biomarkers, Economic and Financial Impacts of Cancer, Cholangiocarcinoma and Gallbladder Cancer Studies
Most-Cited Works
- → Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma(2017)2,174 cited
- → Health-related quality of life results from the phase III CheckMate 067 study(2017)95 cited
- → Sequential Treatment Approaches in the Management of BRAF Wild-Type Advanced Melanoma: A Cost–Effectiveness Analysis(2018)27 cited
- → The Economic Burden of Posttransplant Events in Renal Transplant Recipients in Europe(2014)22 cited
- → Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England(2018)20 cited
- → Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS(2020)18 cited